医学
新辅助治疗
乳腺癌
肿瘤科
内科学
前瞻性队列研究
临床试验
癌症
作者
Paul Jank,Thomas Karn,Marion van Mackelenbergh,Judith Lindner,Denise Treue,Jens Huober,Knut Engels,Christine Solbach,Kurt Diebold,Frederik Marmé,Volkmar Müller,Andreas Schneeweiß,Hans‐Peter Sinn,Tanja Fehm,Christian Schem,Elmar Stickeler,Peter A. Fasching,Jan Budczies,Bärbel Felder,Valentina Nekljudova
标识
DOI:10.1158/1078-0432.ccr-24-0459
摘要
The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens.
科研通智能强力驱动
Strongly Powered by AbleSci AI